These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 37046703)

  • 1. Metabolic Interventions in Tumor Immunity: Focus on Dual Pathway Inhibitors.
    Chen M; Lan H; Yao S; Jin K; Chen Y
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
    Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
    Front Immunol; 2021; 12():774103. PubMed ID: 35250965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic interventions: A new insight into the cancer immunotherapy.
    Yu T; Dong T; Eyvani H; Fang Y; Wang X; Zhang X; Lu X
    Arch Biochem Biophys; 2021 Jan; 697():108659. PubMed ID: 33144083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
    Sasidharan Nair V; Saleh R; Toor SM; Cyprian FS; Elkord E
    Cancer Immunol Immunother; 2021 Aug; 70(8):2103-2121. PubMed ID: 33532902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic reprogramming of immune cells in pancreatic cancer progression.
    Xiang H; Yang R; Tu J; Xi Y; Yang S; Lv L; Zhai X; Zhu Y; Dong D; Tao X
    Biomed Pharmacother; 2023 Jan; 157():113992. PubMed ID: 36395610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response.
    Dabi YT; Andualem H; Degechisa ST; Gizaw ST
    Biologics; 2022; 16():35-45. PubMed ID: 35592358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy.
    Wegiel B; Vuerich M; Daneshmandi S; Seth P
    Front Oncol; 2018; 8():284. PubMed ID: 30151352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
    Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
    Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses.
    Nazari N; Jafari F; Ghalamfarsa G; Hadinia A; Atapour A; Ahmadi M; Dolati S; Rostamzadeh D
    Immunol Cell Biol; 2021 Sep; 99(8):814-832. PubMed ID: 33988889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
    Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
    Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages.
    Wang Y; Wang D; Yang L; Zhang Y
    Chin Med J (Engl); 2022 Oct; 135(20):2405-2416. PubMed ID: 36385099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
    Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
    Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cancer metabolic reprogramming and immune response.
    Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
    Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.